Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Todd W. Bauer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-9516-1848; OpenAlex author ID A5077902939, A5105367259. Sources: OpenAlex.

Their work

Papers
30 (first author 1, last author 11)
Trials
0
Grants
0
Labs led
2
Collaborators
79
Papers, trials and grants by year

2011: 4 papers · 2012: none · 2013: 2 papers · 2014: 3 papers · 2015: none · 2016: 2 papers · 2017: none · 2018: 3 papers · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: 2 papers · 2023: 3 papers · 2024: 4 papers · 2025: 1 paper · 2026: 3 papers

Papers 30

  1. Reactivation of DRP1 plays a functional role in resistance to MEK inhibition in pancreatic cancer cells. Co-author DOI 10.1038/s41416-026-03542-7↗
  2. PTEN Oxidation Promotes Constitutive PI3K Signaling and Inducible Macropinocytosis in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-24-4501↗
  3. KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment. Co-author DOI 10.1158/0008-5472.can-25-2630↗
  4. PRMT5 Identified as a Viable Target for Combination Therapy in Preclinical Models of Pancreatic Cancer. Last author DOI 10.3390/biom15070948↗
  5. Survival benefit associated with screening of patients at elevated risk for pancreatic cancer. Last author DOI 10.1002/jso.27784↗
  6. Dielectrophoretic enrichment of live chemo-resistant circulating-like pancreatic cancer cells from media of drug-treated adherent cultures of solid tumors. Co-author DOI 10.1039/d3lc00804e↗
  7. A Histone Methylation-MAPK Signaling Axis Drives Durable Epithelial-Mesenchymal Transition in Hypoxic Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-22-2945↗
  8. PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-23-1444↗
  9. Supervised learning on impedance cytometry data for label-free biophysical distinction of pancreatic cancer cells versus their associated fibroblasts under gem… Co-author DOI 10.1016/j.bios.2023.115262↗
  10. Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline r… Co-author DOI 10.1136/jitc-2023-007586↗
  11. Interrogating the CD27:CD70 axis in αCD40-dependent control of pancreatic adenocarcinoma. Co-author DOI 10.3389/fcell.2023.1173686↗
  12. ISL2 is a putative tumor suppressor whose epigenetic silencing reprograms the metabolism of pancreatic cancer. Co-author DOI 10.1016/j.devcel.2022.04.014↗
  13. Automated biophysical classification of apoptotic pancreatic cancer cell subpopulations by using machine learning approaches with impedance cytometry. Co-author DOI 10.1039/d2lc00304j↗
  14. Using Graph Representation Learning to Predict Salivary Cortisol Levels in Pancreatic Cancer Patients. Co-author DOI 10.1007/s41666-021-00098-4↗
  15. Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells. Co-author DOI 10.1073/pnas.2009899117↗
  16. ISL2 is an epigenetically silenced tumor suppressor and regulator of metabolism in pancreatic cancer Co-author DOI 10.1101/2020.05.23.112839↗
  17. CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response. Co-author DOI 10.1038/s41467-018-06676-2↗
  18. CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-17-2283↗
  19. Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer. Co-author DOI 10.18632/oncotarget.23944↗
  20. From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. First author DOI 10.1186/s40425-016-0119-z↗
  21. Adjuvant Trametinib Delays the Outgrowth of Occult Pancreatic Cancer in a Mouse Model of Patient-Derived Liver Metastasis. Last author DOI 10.1245/s10434-016-5116-4↗
  22. Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer. Last author DOI 10.1016/j.neo.2014.06.004↗
  23. A thirteen-gene expression signature predicts survival of patients with pancreatic cancer and identifies new genes of interest. Last author DOI 10.1371/journal.pone.0105631↗
  24. Accelerated fraction radiotherapy with capecitabine as neoadjuvant therapy for borderline resectable pancreatic cancer. Co-author PMID 24558510↗
  25. Clinical, molecular and genetic validation of a murine orthotopic xenograft model of pancreatic adenocarcinoma using fresh human specimens. Last author DOI 10.1371/journal.pone.0077065↗
  26. Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epiderma… Last author DOI 10.1593/neo.121712↗
  27. Plectin-1 as a novel biomarker for pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-10-0999↗
  28. Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Last author DOI 10.1158/1535-7163.mct-11-0261↗
  29. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Last author DOI 10.1245/s10434-010-1456-7↗
  30. Pancreas-protocol imaging at a high-volume center leads to improved preoperative staging of pancreatic ductal adenocarcinoma. Last author DOI 10.1245/s10434-011-1693-4↗

Closest collaborators

The 25 strongest of 79 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. David F. Kashatus · 4 shared papers, 2022–2026 · strength 0.94
  2. Sarbajeet Nagdas · 5 shared papers, 2018–2025 · strength 0.78
  3. William J. Kane · 4 shared papers, 2020–2025 · strength 0.76
  4. Nathan S. Swami · 3 shared papers, 2022–2024 · strength 0.63
  5. Carlos Honrado · 3 shared papers, 2022–2024 · strength 0.63
  6. Craig Lee Slingluff · 5 shared papers, 2016–2024 · strength 0.54
  7. Rachel A. Burge · 2 shared papers, 2026 · strength 0.49
  8. G. Aaron Hobbs · 2 shared papers, 2026 · strength 0.49
  9. Osama E. Rahma · 4 shared papers, 2016–2024 · strength 0.45
  10. Matthew J. Reilley · 3 shared papers, 2021–2024 · strength 0.43
  11. Armita Salahi · 2 shared papers, 2022–2023 · strength 0.40
  12. Xiaolong Wei · 2 shared papers, 2020–2025 · strength 0.40
  13. Mazhar Adli · 4 shared papers, 2018–2022 · strength 0.37
  14. Timothy N. J. Bullock · 3 shared papers, 2018–2023 · strength 0.37
  15. Salma Sharmin · 1 shared paper, 2026 · strength 0.33
  16. Matthew H. G. Katz · 2 shared papers, 2023–2024 · strength 0.30
  17. Victoire Cardot‐Ruffino · 2 shared papers, 2023–2024 · strength 0.30
  18. Andressa Dias Costa · 2 shared papers, 2023–2024 · strength 0.30
  19. Chee‐Chee Stucky · 2 shared papers, 2023–2024 · strength 0.30
  20. Rawad Elias · 2 shared papers, 2023–2024 · strength 0.30
  21. Nipun B. Merchant · 2 shared papers, 2023–2024 · strength 0.30
  22. Brian Matthew Wolpin · 2 shared papers, 2023–2024 · strength 0.30
  23. Tanios Bekaii‐Saab · 2 shared papers, 2023–2024 · strength 0.30
  24. Jonathan Andrew Nowak · 2 shared papers, 2023–2024 · strength 0.30
  25. Stephanie K. Dougan · 2 shared papers, 2023–2024 · strength 0.30

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.